Stability of HbA1c in whole blood is a critical pre-analytical consideration that directly affects the accuracy of diabetes diagnosis and glycaemic monitoring. HbA1c, or glycated haemoglobin, reflects average blood glucose over the preceding two to three months and is the primary diagnostic marker for type 2 diabetes in the UK, with a threshold of 48 mmol/mol under NICE guideline NG28. However, even this robust biomarker can yield unreliable results if samples are collected, stored, or transported incorrectly. This article outlines how long HbA1c remains stable in whole blood, the factors that influence stability, and the best-practice recommendations for UK clinical and laboratory settings.

What Is HbA1c and Why Sample Stability Matters

HbA1c reflects average blood glucose over two to three months and is the UK's primary diagnostic marker for type 2 diabetes at 48 mmol/mol; sample degradation before analysis can produce falsely low or high results, risking misdiagnosis or inappropriate treatment changes.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c, or glycated haemoglobin, is formed when glucose in the bloodstream binds irreversibly to haemoglobin within red blood cells — a process known as non-enzymatic glycation. Because red blood cells have a lifespan of approximately 120 days, HbA1c reflects average blood glucose concentrations over the preceding two to three months. This makes it a valuable biomarker for diagnosing type 2 diabetes and monitoring long-term glycaemic control in people living with diabetes, in line with NICE guideline NG28 and WHO 2011 guidance on the use of HbA1c in diagnosis.

In the UK, a diagnostic threshold of 48 mmol/mol (6.5%) or above is used to diagnose type 2 diabetes, with results reported in IFCC-aligned mmol/mol units as mandated by NHS standardisation policy.

Important diagnostic caveats: HbA1c is not appropriate as a diagnostic or monitoring tool in all circumstances. It should not be used for diagnosis or may give unreliable results in the following situations, where glucose-based testing (fasting plasma glucose or oral glucose tolerance test) should be used instead:

• Pregnancy (including gestational diabetes)

• Haemoglobinopathies with a significant effect on red cell turnover (e.g., sickle cell disease, thalassaemia major)

• Haemolytic anaemia

• Recent blood transfusion

• Chronic kidney disease stage 4–5

• Acute illness or acute hyperglycaemia

• Children and young people (where clinical judgement and glucose-based tests are preferred)

Clinicians should refer to NICE NG28 and NHS guidance for a full list of circumstances where HbA1c is unreliable.

The clinical utility of HbA1c depends not only on the analytical method used but also on the integrity of the blood sample at the point of measurement. If a sample degrades before analysis, the result may be falsely low or high, potentially leading to misdiagnosis or inappropriate changes in treatment. For example, a falsely low HbA1c could mask poor glycaemic control, while a falsely elevated result might prompt unnecessary intensification of therapy.

Sample stability is therefore a critical pre-analytical variable — one that is often overlooked in busy clinical and laboratory settings. Understanding how long HbA1c remains reliable in whole blood, and under what conditions, is essential for:

• Laboratories processing samples from remote collection sites

• GP practices and community clinics where samples may not be analysed immediately

• Patients undergoing home phlebotomy or postal testing services

Ensuring sample integrity from the moment of collection through to laboratory analysis underpins the accuracy of HbA1c reporting and, ultimately, patient safety.

How Long HbA1c Remains Stable in Whole Blood Samples

HbA1c in EDTA whole blood is generally stable for 24–72 hours at room temperature and up to seven days refrigerated at 2–8°C, though stability limits are method- and platform-dependent and must be confirmed with the local laboratory.

The stability of HbA1c in whole blood is generally considered robust compared with many other biochemical analytes. This is because glycation of haemoglobin forms a stable, covalent bond that does not readily reverse under normal storage conditions. Instability, when it occurs, typically arises from red cell degradation and lysis rather than from reversal of glycation itself; once haemoglobin is released from lysed red cells, certain analytical methods may be affected depending on the degree of haemolysis and the assay platform in use.

It is important to note that specific stability limits are method- and platform-dependent. Manufacturers of HbA1c analysers (such as the Roche Tina-quant HbA1c, Bio-Rad Variant II Turbo, and Tosoh G8) publish validated specimen requirements and stability limits in their Instructions for Use (IFUs). Laboratories accredited to ISO 15189 (via UKAS) are required to validate and document their own pre-examination acceptance criteria, including temperature and time limits. Clinicians and phlebotomists should always follow their local laboratory's sample requirements handbook for site-specific instructions.

As a general guide, commonly cited stability windows for EDTA whole blood are:

• Room temperature (approximately 18–25°C): Most guidance and manufacturer IFUs recommend analysis within 24 to 72 hours of collection. Beyond this window, changes in the sample matrix — including red cell degradation and, in some circumstances, bacterial contamination — may compromise result accuracy on certain platforms.

• Refrigerated (2–8°C): Samples are generally considered stable for up to seven days. Some analyser IFUs and laboratory protocols validate stability up to 14 days under optimal refrigeration, though this is platform-specific and not universally applicable.

• Frozen (−20°C or below): HbA1c has been shown to remain stable for several months under frozen conditions. However, frozen storage of routine patient samples is rarely necessary or validated in standard clinical practice; it is primarily used for quality control materials, proficiency testing specimens, or research purposes as specified in relevant IFUs. Repeated freeze-thaw cycles should be avoided, as these can cause haemolysis and introduce analytical variability.

Because stability limits vary by method, laboratories should not apply a single universal window without reference to their validated local protocols and the relevant manufacturer IFU.

Factors That Affect HbA1c Stability in Whole Blood

Temperature is the most important stability variable, while haemolysis, haemoglobin variants, incorrect anticoagulant, and underfilled tubes are additional pre-analytical factors that can compromise HbA1c accuracy.

Several pre-analytical and biological factors can influence the stability of HbA1c in whole blood samples, and awareness of these is important for both laboratory staff and clinicians requesting the test.

Temperature is the single most important variable. Elevated temperatures accelerate red cell degradation and may promote bacterial growth, both of which can compromise the sample. Temperatures below 0°C without controlled freezing can cause haemolysis, releasing haemoglobin into the plasma and potentially interfering with certain analytical methods.

Haemolysis — whether caused by poor venepuncture technique, vigorous mixing of the sample tube, or inappropriate storage — is a significant source of pre-analytical error. It is worth noting that most HbA1c assay methods deliberately lyse red cells as part of the analytical process; however, gross in-vitro haemolysis occurring before analysis may still affect results depending on the method and the degree of haemolysis. Whether a haemolysed sample is accepted or rejected depends on local laboratory policy and the specific analytical platform. Clinicians should follow their laboratory's published rejection criteria rather than assuming all haemolysed samples will be refused.

Certain haemoglobin variants, such as HbS, HbC, and HbE, can interfere with HbA1c measurement. Interference patterns are method-dependent and affect both ion-exchange high-performance liquid chromatography (HPLC) and immunoassay methods to varying degrees. Laboratories should use IFCC-aligned, NGSP-certified methods and be informed of suspected haemoglobin variants so that appropriate action — such as using an alternative method or flagging the result — can be taken. The UK NEQAS for HbA1c provides educational materials on variant interference relevant to UK laboratory practice.

Other relevant factors include:

• Anticoagulant type: EDTA is the recommended anticoagulant for HbA1c; fluoride-oxalate tubes used for glucose measurement are not suitable for HbA1c. Serum tubes are also inappropriate.

• Sample volume: Underfilling tubes can alter the blood-to-anticoagulant ratio, potentially affecting cell integrity and result validity.

• Inappropriate tube type: Using a serum or clotted specimen tube for HbA1c is not appropriate; EDTA whole blood does not clot, and the use of non-EDTA tubes should be avoided unless explicitly validated by the local laboratory for a specific platform.

Understanding these variables helps laboratories and clinical teams implement robust pre-analytical protocols.

Storage Temperature and Tube Type Recommendations

EDTA tubes are the UK standard for HbA1c collection; samples should be analysed within 24–72 hours at room temperature or within seven days if refrigerated at 2–8°C, with site-specific limits confirmed via the local laboratory handbook.

Correct sample collection and storage are fundamental to obtaining a reliable HbA1c result. The following recommendations reflect current best practice in UK laboratory medicine and align with guidance from professional bodies including the Association for Clinical Biochemistry and Laboratory Medicine (ACB), as well as ISO 15189 accreditation requirements for pre-examination processes.

Recommended tube type: Whole blood for HbA1c should be collected into EDTA (K2 or K3 EDTA; purple/lavender-top) tubes. EDTA chelates calcium ions, preventing coagulation and preserving red blood cell integrity. Lithium heparin (green-top) tubes may be acceptable on some analytical platforms where this has been explicitly validated by the manufacturer and the local laboratory, but EDTA remains the UK standard recommendation. Serum tubes and fluoride-oxalate tubes are not appropriate for HbA1c measurement.

Storage and transport temperatures (as a general guide; always confirm with local laboratory and manufacturer IFU):

• Room temperature (18–25°C): Analyse within 24–72 hours of collection

• Refrigerated (2–8°C): Stable for up to 7 days; some platforms validate up to 14 days — confirm with local laboratory

• Frozen (−20°C or below): Suitable for long-term storage of quality control and proficiency testing materials; not routinely used for patient samples unless specifically validated; avoid repeated freeze-thaw cycles

Practical storage advice:

• Do not store samples adjacent to ice packs without insulation, as localised freezing can cause haemolysis

• Gently invert the tube 8–10 times immediately after collection to ensure adequate mixing with anticoagulant

• Avoid vigorous shaking, which promotes haemolysis

• Samples should be transported in appropriate cool boxes when sent from remote sites to central laboratories

Local laboratories accredited to ISO 15189 (via UKAS) are required to validate and document their pre-examination acceptance criteria, including stability limits. Clinicians should always refer to their laboratory's sample requirements handbook for site-specific, validated instructions rather than relying solely on general guidance.

Regulatory and Quality Framework for HbA1c Sample Handling in the UK

HbA1c testing in the UK is governed by NICE NG28, MHRA IVD device regulation, ISO 15189 laboratory accreditation via UKAS, and mandatory participation in UK NEQAS external quality assurance schemes.

In the United Kingdom, HbA1c testing sits within a framework of national guidance, device regulation, and laboratory accreditation requirements aimed at ensuring analytical quality and patient safety.

Clinical use: The NHS recommends HbA1c as the primary diagnostic test for type 2 diabetes (at a threshold of 48 mmol/mol or above) and for monitoring glycaemic control in people with established diabetes, in line with NICE guideline NG28. Results must be reported in IFCC-aligned mmol/mol units, as mandated by the UK HbA1c standardisation initiative supported by NHS Diabetes, Diabetes UK, and the Royal Colleges.

Device regulation: The Medicines and Healthcare products Regulatory Agency (MHRA) regulates in vitro diagnostic (IVD) devices used for HbA1c measurement in the UK under the UKCA/CE marking framework. Manufacturers are required to validate their instruments against internationally recognised standards, including the IFCC reference measurement procedure for HbA1c. The MHRA's role is the regulation of IVD devices; responsibility for controlling pre-analytical variables — including sample handling and storage — sits within the laboratory's own quality management system.

Laboratory accreditation: NHS laboratories are expected to comply with ISO 15189 accreditation standards, assessed by UKAS (United Kingdom Accreditation Service). ISO 15189 includes specific requirements for pre-examination processes such as sample collection, transport, storage, and stability validation. Under these requirements, laboratories must document and validate their own acceptance criteria for specimen stability, and must participate in relevant external quality assessment (EQA) schemes.

External quality assurance: The UK National External Quality Assessment Service (UK NEQAS) operates an HbA1c quality assurance scheme that monitors laboratory performance across the country. For laboratories accredited to ISO 15189, participation in a relevant EQA scheme such as UK NEQAS for HbA1c is a requirement, not merely a recommendation. Laboratories that identify consistent pre-analytical issues — including sample degradation — are expected to investigate root causes and implement corrective actions as part of their quality management system.

Ensuring Accurate HbA1c Results in Clinical Practice

Reliable HbA1c results require correct EDTA tube use, prompt refrigerated transport, and disclosure of relevant clinical factors such as haemoglobin variants or recent transfusion; results inconsistent with the clinical picture should prompt repeat testing or glucose-based alternatives.

Achieving reliable HbA1c results requires a coordinated approach across the entire testing pathway — from patient preparation through to result reporting and clinical interpretation. Both clinical and laboratory teams share responsibility for maintaining pre-analytical quality.

For clinicians and phlebotomists, key actions include:

• Using the correct EDTA tube and ensuring adequate fill volume

• Gently inverting the tube immediately after collection

• Labelling samples accurately and recording the time of collection

• Ensuring samples are stored and transported at the correct temperature without undue delay

• Informing the laboratory of any relevant clinical factors, such as known haemoglobin variants, recent blood transfusion (which can falsely lower HbA1c by diluting glycated red cells with transfused non-glycated cells), haemolytic anaemia, or other conditions listed in the diagnostic caveats above

• Recognising when HbA1c is not the appropriate test and using glucose-based testing (fasting plasma glucose or oral glucose tolerance test) instead, in line with NICE NG28

For patients, particularly those using home phlebotomy or postal testing kits, it is important to follow the instructions provided carefully. Samples should be posted promptly and not left in warm environments such as car gloveboxes or sunny windowsills. Home and postal HbA1c services should only be used where the service has validated its transport conditions and stability limits, and where analysis is performed by an ISO 15189-accredited laboratory providing traceable results in mmol/mol.

When to seek advice or repeat testing: If an HbA1c result appears inconsistent with a patient's clinical picture — for example, a low HbA1c despite persistently elevated capillary glucose readings — clinicians should consider whether a pre-analytical issue or an underlying condition affecting red cell turnover may have affected the sample. In such cases, repeating the test with careful attention to sample handling, or using an alternative glucose-based test, is advisable before making significant treatment decisions.

Ultimately, the stability of HbA1c in whole blood is generally good when samples are handled correctly, but it is not unconditional and is dependent on the analytical platform in use. A systematic, protocol-driven approach to sample collection, storage, and transport — guided by local laboratory handbooks and ISO 15189-validated acceptance criteria — remains the most effective safeguard against pre-analytical error and ensures that HbA1c continues to serve as a trustworthy guide to glycaemic management in clinical practice.

Frequently Asked Questions